

**Table S3. Patients' Characteristics**

Age	median	49.8	
	range	35~69	
		<i>n</i>	Percentage
Menstrual status	pre	29	37.7%
	peri	17	22.0%
	post	31	40.3%
Clinical stage at diagnosis	I	0	0
	II	41	53.2%
	III	36	46.8%
	IV	0	0
Tumor size	T1	0	0
	T2	44	57.1%
	T3	29	37.7%
	T4	4	5.2%
Clinical Node status	N0	13	8.3%
	N1	45	58.4%
	N2	16	20.8%
	N3	3	5%
Breast surgery	Breast conserving surgery	18	23.4%
	Mastectomy	59	76.6%
Radiotherapy	Nil	1	1.3%
	Breast	38	49.4%
	Chest wall	38	49.4%
ER	Positive	50	64.9%
	Negative	27	35.1%
Her-2	Positive	30	39.0%
	Negative	47	61.0%
Tumor grade	G1	21	27.3%
	G2	35	45.5%
	G3	21	27.3%
Neoadjuvant chemotherapy	AC*4 followed by T*4	27	35.1%
	TAC*6	50	54.9%

Note: AC\*4 followed by T\*4: four 21-day cycles of AC (Doxorubicin: 60 mg/m<sup>2</sup> on day 1, Cyclophosphamide: 600 mg/m<sup>2</sup> on day 1) followed by four 21-day cycles of Docetaxel (100 mg/m<sup>2</sup> on day 1); TAC\*6: six 21-day cycles of TAC (Docetaxel: 75 mg/m<sup>2</sup> on day 1, Doxorubicin: 50 mg/m<sup>2</sup> on day 1, Cyclophosphamide: 500 mg/m<sup>2</sup> on day 1)